In addition, ORR, DCR, and PFS of atezolizumab rechallenge after refractory anti-PD-1 antibodies for 18 patients with NSCLC were 0%, 38.9%, and 2.9 months, respectively [17]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.